Evidence map›Paper›PMID 31286104›Full record

ArticleJournal of the Endocrine Society2019

CLARITY-BPA Program in Rats: Is It Translatable to Humans?

Todd Hagobian

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Todd HagobianDepartment of Kinesiology and Public Health, Center for Health Research Center, California Polytechnic State University, San Luis Obispo, California.ORCID 0000-0002-9833-8215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Consortium Linking Academic and Regulatory Insights on BPA Toxicity (CLARITY-BPA) program was the most comprehensive study to date examining a full range of health effects of varying bisphenol A (BPA) exposure in rats. The major concern of the CLARITY-BPA program that has not previously been discussed is whether exposing rats to varying doses to BPA is translatable to humans, even at the "typical" exposure ranges for humans. This perspective will provide evidence that the vast majority of pharmaceutical drug development and other trials in animals have not been replicated in human randomized studies. Similarly, to truly understand whether BPA exposure affects human health, clinical trials are needed to examine BPA administration in humans in controlled settings.

Indexed as

bisphenol ACLARITYdiabetesobesityoral consumption

Identifiers

PMID31286104
PMCPMC6608553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.